The “added value” of enrolling hematological patients in clinical trials: a single-center experience

The “added value” of enrolling hematological patients in clinical trials: a single-center experience

Pharmaceutical expenditure is constantly growing, in parallel with the increasing incidence of cancers and drug development costs. Enrolling patients in clinical trials provides countless advantages both for patients and the healthcare system; the pharmacoeconomic point of view is usually the least...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefano Loiacono, Elisa Lucchini, Maria Chiara Rossetti, Clara Palmieri, Irina Cebulec, Riccardo Provasi, Martina Lena, Eleonora De Bellis, Chiara Roni, Francesco Zaja
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Hematology
Subjects:
hematology
costs
pharmacoeconomics
clinical trials
drugs
avoided pharmaceutical expenditure
Online Access:https://www.frontiersin.org/articles/10.3389/frhem.2025.1613099/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/frhem.2025.1613099/full

Similar Items